Read by QxMD icon Read


Werner Benzer, Bernhard Rauch, Jean-Paul Schmid, Ann Dorthe Zwisler, Paul Dendale, Constantinos H Davos, Evangelia Koudi, Attila Simon, Ana Abreu, Nana Pogosova, Dan Gaita, Bojan Miletic, Gerd Bönner, Taoufik Ouarrak, Hannah McGee
AIM: Results from EuroCaReD study should serve as a benchmark to improve guideline adherence and treatment quality of cardiac rehabilitation (CR) in Europe. METHODS AND RESULTS: Data from 2.054 CR patients in 12 European countries were derived from 69 centres. 76% were male. Indication for CR differed between countries being predominantly ACS in Switzerland (79%), Portugal (62%) and Germany (61%), elective PCI in Greece (37%), Austria (36%) and Spain (32%), and CABG in Croatia and Russia (36%)...
November 11, 2016: International Journal of Cardiology
R Giorgi
BACKGROUND: Net survival, the survival probability that would be observed, in a hypothetical world, where the cancer of interest would be the only possible cause of death, is a key indicator in population-based cancer studies. Accounting for mortality due to other causes, it allows cross-country comparisons or trends analysis and provides a useful indicator for public health decision-making. The objective of this study was to show how the creation and formalization of a network comprising established research teams, which already had substantial and complementary experience in both cancer survival analysis and methodological development, make it possible to meet challenges and thus provide more adequate tools, to improve the quality and the comparability of cancer survival data, and to promote methodological transfers in areas of emerging interest...
October 2016: Revue D'épidémiologie et de Santé Publique
Fernanda Costa Svedman, Demetris Pillas, Aliki Taylor, Moninder Kaur, Ragnar Linder, Johan Hansson
BACKGROUND: Given the increasing incidence in cutaneous malignant melanoma (CMM) and the recent changes in the treatment landscape, it is important to understand stage-specific overall and recurrence-free survival patterns in Europe. Despite publications such as EUROCARE-5, there is limited information on stage-specific survival for CMM in Europe. METHOD: We carried out a systematic literature review to provide an up-to-date summary of stage-specific survival and recurrence-free survival patterns in patients with CMM in Europe...
2016: Clinical Epidemiology
Vesna Zadnik, Tina Žagar, Maja Primic Žakelj
BACKGROUND: Cancer patients' survival is an extremely important but complex indicator for assessing regional or global inequalities in diagnosis practices and clinical management of cancer patients. The population-based cancer survival comparisons are available through international projects (i.e. CONCORD, EUROCARE, OECD Health Reports) and online systems (SEER, NORDCAN, SLORA). In our research we aimed to show that noticeable differences in cancer patients' survival may not always reflect the real inequalities in cancer care, but can also appear due to variations in the applied methodology for relative survival calculation...
June 1, 2016: Zdravstveno Varstvo
Milena Villarini, Chiara Lanari, Daniele Nucci, Vincenza Gianfredi, Tiziana Marzulli, Franco Berrino, Alessandra Borgo, Eleonora Bruno, Giuliana Gargano, Massimo Moretti, Anna Villarini
INTRODUCTION: Breast cancer (BC) is the most frequent cancer in Europe and the International Agency for Research on Cancer (IARC) has estimated over 460 000 incident cases per year. Survival among patients with BC has increased in the past decades and EUROCARE-5 has estimated a 5-year relative survival rate of 82% for patients diagnosed in 2000-2007. There is growing evidence that lifestyle (such as a diet based on Mediterranean principles associated with moderate physical activity) may influence prognosis of BC; however, this information is not currently available to patients and is not considered in oncology protocols...
June 1, 2016: BMJ Open
Annalisa Trama, Laura Botta, Roberto Foschi, Andrea Ferrari, Charles Stiller, Emmanuel Desandes, Milena Maria Maule, Franco Merletti, Gemma Gatta
BACKGROUND: Data from EUROCARE have consistently shown lower survival for adolescents and young adults (AYAs; aged 15-24 years) than for children (0-14 years) for most cancers that affect both groups, and modest survival improvements up to 2000-02. AYAs have longer survival than that of adults for most cancers. We used the latest definition of AYAs (aged 15-39 years) and provided estimates of 5-year relative survival for European AYAs with cancer diagnosed in 2000-07, compared with children and adults (40-69 years) with cancer, and assessed survival improvements over time...
July 2016: Lancet Oncology
Farhad Moradpour, Ali Gholami, Mohammad Salehi, Kamiar Mansori, Mohammad Reza Maracy, Setareh Javanmardi, Abdolhalim Rajabi, Yousef Moradi, Mahmod Khodadost
Gastrointestinal cancers remain the most prevalent cancers in many developing countries such as Iran. The aim of this study was to estimate incidence, prevalence and mortality, as well as time trends for gastrointestinal cancers in Isfahan province of Iran for the period 2001 to 2010 and to project these estimates to the year 2020. Estimates were driven by applying the MIAMOD method (a backward calculation approach using mortality and relative survival rates). Mortality data were obtained from the Ministry of Health and the relative survival rate for all gastrointestinal cancers combined was derived from the Eurocare 3 study...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Leszek Siemion, Jedrzej Bandurski, Stanisław Malinger
INTRODUCTION: Gastric cancer is the third leading cause of death from cancer worldwide in both sexes, following lung and breast cancer. The incidence of gastric cancer in Poland is approximately 5% in men and approximately 2.5% in women, among the complete incidence of cancers. Deaths from gastric cancer in men in Poland in 2009 amounted to 6.6%, while in women--4.6%. The highest mortality rate in men is observed in the Lubuskie, Podkarpackie, Slaskie and Opolskie provinces. European average 5-year survival in the EUROCARE-4 study is 24...
2015: Przegla̧d Lekarski
Morgane Mounier, Nadine Bossard, Laurent Remontet, Aurélien Belot, Pamela Minicozzi, Roberta De Angelis, Riccardo Capocaccia, Jean Iwaz, Alain Monnereau, Xavier Troussard, Milena Sant, Marc Maynadié, Roch Giorgi
BACKGROUND: Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collaborative European population-based cancer registries (EUROCARE)...
November 2015: Lancet Haematology
Roberta De Angelis, Pamela Minicozzi, Milena Sant, Luigino Dal Maso, David H Brewster, Gemma Osca-Gelis, Otto Visser, Marc Maynadié, Rafael Marcos-Gragera, Xavier Troussard, Dominic Agius, Paolo Roazzi, Elisabetta Meneghini, Alain Monnereau
BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625,000 adult patients diagnosed in 2000-2007 and followed up to 2008...
September 6, 2015: European Journal of Cancer
Silvia Francisci, Pamela Minicozzi, Daniela Pierannunzio, Eva Ardanaz, Andrea Eberle, Tom K Grimsrud, Arnold Knijn, Ugo Pastorino, Diego Salmerón, Annalisa Trama, Milena Sant
BACKGROUND: Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. METHODS: Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000-2007 by country/region, age and gender, and over time trends in 1999-2007 were estimated...
September 5, 2015: European Journal of Cancer
Otto Visser, Eva Ardanaz, Laura Botta, Milena Sant, Andrea Tavilla, Pamela Minicozzi
BACKGROUND: Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000-2007 in Europe. METHODS: For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included...
September 5, 2015: European Journal of Cancer
Rafael Marcos-Gragera, Sandra Mallone, Lambertus A Kiemeney, Loreto Vilardell, Núria Malats, Yves Allory, Milena Sant
BACKGROUND: This work presents relative survival estimates regarding urinary tract tumours among adult patients (age⩾15years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000-2007, and on survival time trends from 1999-2001 to 2005-2007. METHODS: Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries...
September 5, 2015: European Journal of Cancer
Annalisa Trama, Roberto Foschi, Nerea Larrañaga, Milena Sant, Rafael Fuentes-Raspall, Diego Serraino, Andrea Tavilla, Liesbet Van Eycken, Nicola Nicolai
BACKGROUND: We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. METHODS: The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000-2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999-2007 were estimated by the period approach...
September 6, 2015: European Journal of Cancer
Milena Sant, Maria Dolores Chirlaque Lopez, Roberto Agresti, Maria José Sánchez Pérez, Bernd Holleczek, Magdalena Bielska-Lasota, Nadya Dimitrova, Kaire Innos, Alexander Katalinic, Hilde Langseth, Nerea Larrañaga, Silvia Rossi, Sabine Siesling, Pamela Minicozzi
BACKGROUND: Survival differences across Europe for patients with cancers of breast, uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE studies. In the present EUROCARE-5 study we update survival estimates and investigate changes in country-specific and over time survival, discussing their relationship with incidence and mortality dynamics for cancers for which organised screening programs are ongoing. METHODS: We analysed cases archived in over 80 population-based cancer registries in 29 countries grouped into five European regions...
September 6, 2015: European Journal of Cancer
Emanuele Crocetti, Sandra Mallone, Trude Eid Robsahm, Anna Gavin, Domenic Agius, Eva Ardanaz, Maria-Dolores Chirlaque Lopez, Kaire Innos, Pamela Minicozzi, Lorenzo Borgognoni, Daniela Pierannunzio, Nora Eisemann
BACKGROUND: In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe. METHODS: Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15years and over with a diagnosis of invasive SM in Europe (2000-2007). Survival time trends during 1999-2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered...
September 5, 2015: European Journal of Cancer
Côme Lepage, Riccardo Capocaccia, Monika Hackl, Valerie Lemmens, Esther Molina, Daniela Pierannunzio, Milena Sant, Annalisa Trama, Jean Faivre
BACKGROUND: The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. METHODS: This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers ("biliary tract cancers"), and pancreatic cancer diagnosed in 2000-2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach...
September 5, 2015: European Journal of Cancer
Bernd Holleczek, Silvia Rossi, Agius Domenic, Kaire Innos, Pamela Minicozzi, Silvia Francisci, Monika Hackl, Nora Eisemann, Hermann Brenner
BACKGROUND: Previous population-based studies revealed major variation in survival for patients with colorectal cancer (CRC) in Europe by age and between different countries and regions, but also a sustained improvement in survival for patients with CRC in recent years. This EUROCARE-5 paper aims to update available knowledge from previous studies and to provide the latest survival estimates for CRC patients from Europe. METHODS: The study analysed data of patients diagnosed with CRC from population-based cancer registries diagnosed in 29 European countries...
September 6, 2015: European Journal of Cancer
L A Anderson, A Tavilla, H Brenner, S Luttmann, C Navarro, A T Gavin, B Holleczek, B T Johnston, M B Cook, F Bannon, M Sant
BACKGROUND: European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. MATERIALS AND METHODS: EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS...
September 5, 2015: European Journal of Cancer
Gemma Gatta, Laura Botta, María José Sánchez, Lesley Ann Anderson, Daniela Pierannunzio, Lisa Licitra
BACKGROUND: Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. METHODS: We analysed about 250,000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage...
September 6, 2015: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"